Format

Send to

Choose Destination
Expert Rev Mol Diagn. 2012 Mar;12(2):139-46. doi: 10.1586/erm.12.2.

Using NF-κB as a molecular target for theranostics in radiation oncology research.

Author information

1
Department of Biomedical Imaging & Radiological Sciences, National Yang-Ming University, Taipei, Taiwan.

Abstract

Resistance of cancer cells to chemotherapy and/or radiotherapy is a major challenge to current anticancer treatment. The NF-κB signaling pathway plays an important role in tumor development and progression, and results in unsatisfactory treatment outcome. Inhibition of the NF-κB signaling cascade may sensitize the resistant cancer cells to chemotherapy and/or radiotherapy. Here, the correlation of NF-κB molecules with carcinogenesis and tumor progression, along with its significance in clinical practice, is reviewed. The potential clinical application of NF-κB and its associated molecules as diagnostic and therapeutic targets is also discussed.

PMID:
22369374
DOI:
10.1586/erm.12.2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center